ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2272

Gene Expression Signatures in Monocytes From Primary Antiphospholipd Syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome Identify Specific Pathways Involved in the Pathogenesis of Atherosclerosis and Cardiovascular Disease

Chary Lopez-Pedrera1, Sebastiano Messineo2, Carlos Perez-Sanchez1, Patricia Ruiz-Limon1, Mª Angeles Aguirre3, Rosario M. Carretero-Prieto4, Antonio Rodriguez-Ariza1, Nuria Barbarroja4, Francisco Velasco1, Munther A. Khamashta5, Eduardo Collantes-Estevez1 and Mª Jose Cuadrado6, 1IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 2Dipartimento di Scienze della Salute, Universitá Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Universitá Magna Graecia di Catanzaro, Italy., Catanzaro, Italy, 3Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 4Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, 5Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 6Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Atherosclerosis, Cardiovascular disease, genomics and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Systemic lupus erythematosus (SLE) is characterized by immune-mediated inflammation in multiple organ systems. SLE, primary Antiphospholipid syndrome (APS) and secondary APS (SAPS) share several clinical features, including atherosclerosis (AT) and cardiovascular disease (CVD), but also have some unique distinguishing characteristics. The aim of this study was to identify shared and differential molecular pathways involved in the pathogenesis of AT and CVD in that autoimmune diseases.

Methods:

127 patients (42 APS, 20 SAPS and 56 SLE) and 61 healthy donors were included. Microarray expression profiling was performed in samples of monocytes from these patients and real time RT-PCR of selected genes was used to validate microarray data. Some clinical and inflammatory parameters were also obtained.

Results:

Comparing to controls, the expression of 555, 1224, and 518 genes were found significantly altered in monocytes from SLE, SAPS, and APS patients, respectively. On the other hand, 1243 genes were differentially regulated in APS vs. SLE, and 605 genes in SAPS vs. SLE. Interestingly, only 220 genes were differentially regulated when comparing APS with SAPS. Approximately 25-30% of the total number of altered genes in the three diseases were related to AT, inflammation and CVD (chemoquines/cytokines and their receptors, molecules related to angiogenesis, oxidative stress, mitochondrial dynamics and metabolism, lipid metabolism and cell to cell signalling). A specific AT/CVD/Inflammation-related gene signature was found for each disease. Thus, compared to LES, APS showed alterations in mitochondria biogenesis and function, oxidative stress and antioxidant defense. Besides the interferon signature found SAPS and SLE patients, a number of genes mediating atherosclerotic/inflammatory signalling were found further altered in SAPS. Multivariate analysis showed that IgG aCL titers, which are known risk factors for AT and CVD events in SLE, independently predicted both atherosclerotic and thrombosis in SAPS. Moreover, a higher percentage of SAPS showed increased carotid intimate media thickness than LES patients. We further found a significant correlation of IgG-aCL titers with circulating levels of inflammatory molecules (tPA, MCP-1, TNFα, and IL-2).

Conclusion:

1) Gene expression profiling allows the segregation of APS, SAPS and SLE, with specific signatures explaining the pro-atherosclerotic, pro-thrombotic and inflammatory changes in these highly related autoimmune diseases. 2) The identification of key genes regulating specific pathophysiologic pathways will permit the development of targeted therapies for each autoimmune condition. Supported by JA0246/2009, P08-CVI-04234, and PS09/01809.


Disclosure:

C. Lopez-Pedrera,
None;

S. Messineo,
None;

C. Perez-Sanchez,
None;

P. Ruiz-Limon,
None;

M. A. Aguirre,
None;

R. M. Carretero-Prieto,
None;

A. Rodriguez-Ariza,
None;

N. Barbarroja,
None;

F. Velasco,
None;

M. A. Khamashta,
None;

E. Collantes-Estevez,
None;

M. J. Cuadrado,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gene-expression-signatures-in-monocytes-from-primary-antiphospholipd-syndrome-systemic-lupus-erythematosus-and-lupus-with-antiphospholipid-syndrome-identify-specific-pathways-involved-in-the-pathogen/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology